Design of glycopeptides used to investigate class II MHC binding and T-cell responses associated with autoimmune arthritis

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Andersson, Ida E ^a   Andersson, C David ^a   Batsalova, Tsvetelina ^b   Dzhambazov, Balik ^b   Holmdahl, Rikard ^b   Kihlberg, Jan ^a,c   Linusson, Anna ^c  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; GLYCOPEPTIDE; HLA DR4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; HLA ANTIGEN CLASS 2; LIGAND;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN STRUCTURE; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; VACCINATION; VACCINE PRODUCTION; ANIMAL; ARTHRITIS; BINDING COMPETITION; BIOTINYLATION; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER INTERFACE; DRUG SCREENING; HUMAN; HYBRIDOMA; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BINDING; REGRESSION ANALYSIS; SYNTHESIS;

MURINAE;

AMINO ACID SEQUENCE; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BINDING, COMPETITIVE; BIOTINYLATION; DRUG EVALUATION, PRECLINICAL; GLYCOPEPTIDES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR4 ANTIGEN; HUMANS; HYBRIDOMAS; LEAST-SQUARES ANALYSIS; LIGANDS; MICE; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BINDING; T-LYMPHOCYTES; USER-COMPUTER INTERFACE;

EID: 79952635494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017881     Document Type: Article

References (88)

1. Gregersen PK, Silver J, Winchester RJ, (1987) The Shared Epitope Hypothesis. An Approach to Understanding the Molecular Genetics of Susceptibility to Rheumatoid Arthritis. Arthritis Rheum 30: 1205-1213.
2. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B, (1980) Immunisation Against Heterologous Type II Collagen Induces Arthritis in Mice. Nature 283: 666-668.
3. Wooley PH, Luthra HS, Stuart JM, David CS, (1981) Type II Collagen-Induced Arthritis in Mice. I. Major Histocompatibility Complex (I Region) Linkage and Antibody Correlates. J Exp Med 154: 688-700.
4. Brunsberg U, Gustafsson K, Jansson L, Michaëlsson E, Ährlund-Richter L, et al. (1994) Expression of a Transgenic Class II Ab Gene Confers Susceptibility to Collagen-Induced Arthritis. Eur J Immunol 24: 1698-1702.
5. Bäcklund J, Treschow A, Bockermann R, Holm B, Holm L, et al. (2002) Glycosylation of Type II Collagen is of Major Importance for T Cell Tolerance and Pathology in Collagen-Induced Arthritis. Eur J Immunol 32: 3776-3784.
6. Dzhambazov B, Nandakumar KS, Kihlberg J, Fugger L, Holmdahl R, et al. (2006) Therapeutic Vaccination of Active Arthritis with a Glycosylated Collagen Type II Peptide in Complex with MHC Class II Molecules. J Immunol 176: 1525-1533.
7. Bäcklund J, Carlsen S, Höger T, Holm B, Fugger L, et al. (2002) Predominant Selection of T Cells Specific for the Glycosylated Collagen Type II Epitope (263-270) in Humanized Transgenic Mice and in Rheumatoid Arthritis. Proc Natl Acad Sci USA 99: 9960-9965.
8. Holm B, Bäcklund J, Recio MAF, Holmdahl R, Kihlberg J, (2002) Glycopeptide specificity of helper T cells obtained in mouse models for rheumatoid arthritis. ChemBioChem 3: 1209-1222.
9. Rosloniec EF, Whittington KB, Brand DD, Myers LK, Stuart JM, (1996) Identification of MHC Class II and TCR Binding Residues in the Type II Collagen Immunodominant Determinant Mediating Collagen-Induced Arthritis. Cell Immunol 172: 21-28.
10. Kjellén P, Brunsberg U, Broddefalk J, Hansen B, Vestberg M, et al. (1998) The Structural Basis of MHC Control of Collagen-Induced Arthritis; Binding of the Immunodominant Type II Collagen 256-270 Glycopeptide to H-2Aq and H-2Ap Molecules. Eur J Immunol 28: 755-767.
11. Broddefalk J, Bäcklund J, Almqvist F, Johansson M, Holmdahl R, et al. (1998) T Cells Recognize a Glycopeptide Derived from Type II Collagen in a Model for Rheumatoid Arthritis. J Am Chem Soc 120: 7676-7683.
12. Myers LK, Rosloniec EF, Seyer JM, Stuart JM, Kang AH, (1993) A synthetic peptide analog of a determinant of type-II collagen prevents the onset of collagen-induced arthritis. J Immunol 150: 4652-4658.
13. Holm L, Bockermann R, Wellner E, Bäcklund J, Holmdahl R, et al. (2006) Side-Chain and Backbone Amide Bond Requirements for Glycopeptide Stimulation of T-Cells Obtained in a Mouse Model for Rheumatoid Arthritis. Bioorg Med Chem 14: 5921-5932.
14. Andersson IE, Dzhambazov B, Holmdahl R, Linusson A, Kihlberg J, (2007) Probing molecular interactions within class II MHC A(q)/Glycopeptide/T-cell receptor complexes associated with collagen-induced arthritis. J Med Chem 50: 5627-5643.
15. Andersson IE, Batsalova T, Dzhambazov B, Edvinsson L, Holmdahl R, et al. (2010) Oxazole-modified glycopeptides that target arthritis-associated class II MHC Aq and DR4 proteins. Org Biomol Chem 8: 2931-2940.
16. Andersson EC, Hansen BE, Jacobsen H, Madsen LS, Andersen CB, et al. (1998) Definition of MHC and T Cell Receptor Contacts in the HLA-DR4-Restricted Immunodominant Epitope in Type II Collagen and Characterization of Collagen-Induced Arthritis in HLA-DR4 and Human CD4 Transgenic Mice. Proc Natl Acad Sci USA 95: 7574-7579.
17. Zavala-Ruiz Z, Sundberg EJ, Stone JD, DeOliveira DB, Chan IC, et al. (2003) Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1. J Biol Chem 278: 44904-44912.
18. Smith AB, Benowitz AB, Sprengeler PA, Barbosa J, Guzman MC, et al. (1999) Design and synthesis of a competent pyrrolinone-peptide hybrid ligand for the class II major histocompatibility complex protein HLA-DR1. J Am Chem Soc 121: 9286-9298.
19. de Haan EC, Wauben MHM, Grosfeld-Stulemeyer MC, Kruijtzer JAW, Liskamp RMJ, et al. (2002) Major histocompatibility complex class II binding characteristics of peptoid-peptide hybrids. Bioorg Med Chem 10: 1939-1945.
20. de Haan EC, Wagenaar-Hilbers JPA, Liskamp RMJ, Moret EE, Wauben MHM, (2005) Limited plasticity in T cell recognition of modified T cell receptor contact residues in MHC class II bound peptides. Mol Immunol 42: 355-364.
21. Hanson GJ, Vuletich JL, Bedell LJ, Bono CP, Howard SC, et al. (1996) Design of MHC class II (DR4) ligands using conformationally restricted imino acids at p3 and p5. Bioorg Med Chem Lett 6: 1931-1936.
22. Bolin DR, Swain AL, Sarabu R, Berthel SJ, Gillespie P, et al. (2000) Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. J Med Chem 43: 2135-2148.
23. Evensen E, Joseph-McCarthy D, Weiss GA, Schreiber SL, Karplus M, (2007) Ligand design by a combinatorial approach based on modeling and experiment: application to HLA-DR4. J Comput-Aided Mol Des 21: 395-418.
24. Rognan D, Lauemøller SL, Holm A, Buus S, Tschinke V, (1999) Predicting binding affinities of protein ligands from three-dimensional models: Application to peptide binding to class I major histocompatibility proteins. J Med Chem 42: 4650-4658.
25. Liu ZJ, Dominy BN, Shakhnovich EI, (2004) Structural mining: Self-consistent design on flexible protein-peptide docking and transferable binding affinity potential. J Am Chem Soc 126: 8515-8528.
26. Tong JC, Tan TW, Ranganathan S, (2004) Modeling the structure of bound peptide ligands to major histocompatibility complex. Protein Sci 13: 2523-2532.
27. Wei HY, Tsai KC, Lin TH, (2005) Modeling ligand-receptor interaction for some MHC class IIHLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques. J Chem Inf Model 45: 1343-1351.
28. Linusson A, Wold S, Nordén B, (1998) Statistical molecular design of peptoid libraries. Mol Diversity 4: 103-114.
29. Larsson A, Johansson SMC, Pinkner JS, Hultgren SJ, Almqvist F, et al. (2005) Multivariate design, synthesis, and biological evaluation of peptide inhibitors of FimC/FimH protein-protein interactions in uropathogenic Escherichia coli. J Med Chem 48: 935-945.
30. Nurbo J, Roos AK, Muthas D, Wahlström E, Ericsson DJ, et al. (2007) Design, synthesis and evaluation of peptide inhibitors of Mycobacterium tuberculosis ribonucleotide reductase. J Pept Sci 13: 822-832.
31. Holm L, Frech K, Dzhambazov B, Holmdahl R, Kihlberg J, et al. (2007) Quantitative Structure-Activity Relationship of Peptides Binding to the Class II Major Histocompatibility Complex Molecule Aq Associated with Autoimmune Arthritis. J Med Chem 50: 2049-2059.
32. Holm L, Kjellén P, Holmdahl R, Kihlberg J, (2005) Identification of the Minimal Glycopeptide Core Recognized by T Cells in a Model for Rheumatoid Arthritis. Bioorg Med Chem 13: 473-482.
33. OMEGA (2007) 2.2.0. Openeye Scientific Software Inc. 3600 Cerrillos Road, Suite 1107, Santa Fe, NM 87507.
34. FRED (2007) 2.2.3. Openeye Scientific Software Inc. 3600 Cerrillos Road, Suite 1107, Santa Fe, NM 87507.
35. Box GE, Draper NR, (1987) Empirical Model-Building and Respons Surfaces New York John Wiley & sons, Inc.
36. Kirchmair J, Wolber G, Laggner C, Langer T, (2006) Comparative performance assessment of the conformational model generators omega and catalyst: A large-scale survey on the retrieval of protein-bound ligand conformations. J Chem Inf Model 46: 1848-1861.
37. MOE (2008) 2008.10. Chemical Computing Group Inc. Suite 910- 1010 Sherbrooke St. W, Montreal, Quebec, Canada H3A 2R7.
38. McGann MR, Almond HR, Nicholls A, Grant JA, Brown FK, (2003) Gaussian Docking Functions. Biopolymers 68: 76-90.
39. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Arthurs S, et al. (2000) Deciphering Common Failures in Molecular Docking of Ligand-Protein Complexes. J Comput-Aided Mol Des 14: 731-751.
40. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP, (1997) Empirical scoring functions. 1. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput-Aided Mol Des 11: 425-445.
41. Stahl M, Rarey M, (2001) Detailed Analysis of Scoring Functions for Virtual Screening. J Med Chem 44: 1035-1042.
42. GOLD (2006) 3.1.1. The Cambridge Crystallographic Datacenter. 12 Union Road, Cambridge, CB2 1EZ, U.K.
43. Feher M, (2006) Consensus scoring for protein-ligand interactions. Drug Discov Today 11: 421-428.
44. Oda A, Tsuchida K, Takakura T, Yamaotsu N, Hirono S, (2006) Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexes. J Chem Inf Model 46: 380-391.
45. Perola E, Walters WP, Charifson PS, (2004) A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins: Struct, Funct, Bioinf 56: 235-249.
46. Xing L, Hodgkin E, Liu Q, Sedlock D, (2004) Evaluation and Application of Multiple Scoring Functions for a Virtual Screening Experiment. J Comput-Aided Mol Des 18: 333-344.
47. Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, et al. (2006) A critical assessment of docking programs and scoring functions. J Med Chem 49: 5912-5931.
48. Terp GE, Johansen BN, Christensen IT, Jørgensen FS, (2001) A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities. J Med Chem 44: 2333-2343.
49. Jacobsson M, Lidén P, Stjernschantz E, Boström H, Norinder U, (2003) Improving structure-based virtual screening by multivariate analysis of scoring data. J Med Chem 46: 5781-5789.
50. St. John RC, Draper NR, (1975) D-Optimality for Regression Designs: A Review. Technometrics 17: 15-23.
51. DuMouchel W, Jones B, (1994) A Simple Bayesian Modification of D-Optimal Designs to Reduce Dependence on an Assumed Model. Technometrics 36: 37-47.
52. Wold S, Esbensen K, Geladi P, (1987) Principal Component Analysis. Chemom Intel Lab Sys 2: 37-52.
53. Jackson JE, (1991) A user's guide to principal components New York John Wiley & sons, Inc.
54. Evince (2009) 2.3.0. Umbio AB. Box 7980, 90719 Umeå, Sweden.
55. de Aguiar PF, Bourguignon B, Khots MS, Massart DL, Phan-Than-Luu R, (1995) D-optimal Designs. Chemom Intell Lab Syst 30: 199-210.
56. MODDE (2008) 8.0.2. Umetrics AB. Box 7960, Umeå, Sweden.
57. Wold S, Ruhe A, Wold H, Dunn WJ, (1984) The collinearity problem in linear-regression- the partial least-squares (Pls) approach to generalized Inverses. Siam J Sci Stat Comp 5: 735-743.
58. Wold S, Sjöström M, Eriksson L, (2001) PLS-regression: a basic tool of chemometrics. Chemom Intel Lab Sys 58: 109-130.
59. Lindgren F, Hansen B, Karcher W, Sjöström M, Eriksson L, (1996) Model Validation by Permutation Tests: Applications to Variable Selection. J Chemom 10: 521-532.
60. Eriksson L, Verboom HH, Pejnenburg WJGM, (1996) Multivariate QSAR Modelling of the Rate of Reductive Dehalogenation of Haloalkanes. J Chemom 10: 483-492.
61. SIMCA-P+ (2008) 12.0. Umetrics AB. Box 7960, Umeå, Sweden.
62. Omasits U, Knapp B, Neumann M, Steinhauser O, Stockinger H, et al. (2008) Analysis of key parameters for molecular dynamics of pMHC molecules. Mol Simul 34: 781-793.
63. Maestro (2010) 9.1. Schrödinger, LLC. 120 West 45th Street, 17th Floor, Tower 45, New York, NY, 10036-4041.
64. Desmond Molecular Dynamics System (2010) 2.2. D. E. Shaw Research. New York, NY.
65. Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, et al. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters November 11-17 2006; Tampa, Florida ACM Press, New York.
66. High Performance Computing Center North (HPC2N). www.hpc2n.umu.se.
67. Syed BM, Gustafsson T, Kihlberg J, (2004) 9-BBN as a convenient protecting group in functionalisation of hydroxylysine. Tetrahedron 60: 5571-5575.
68. Krchñák V, Vágner J, Lebl M, (1988) Noninvasive Continuous Monitoring of Solid-Phase Peptide-Synthesis by Acid-Base Indicator. Int J Pept Prot Res 32: 415-416.
69. Hill CM, Liu A, Marshall KW, Mayer J, Jorgensen B, et al. (1994) Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. J Immunol 152: 2890-2898.
70. Corthay A, Bäcklund J, Broddefalk J, Michaëlsson E, Goldschmidt TJ, et al. (1998) Epitope Glycosylation Plays a Critical Role for T Cell Recognition of Type II Collagen in Collagen-Induced Arthritis. Eur J Immunol 28: 2580-2590.
71. Michaëlsson E, Andersson M, Holmdahl R, Engström Å, (1992) Identification of an immunodominant type-II collagen peptide recognized by T cells in H-2q mice: self tolerance at the level of determinant selection. Eur J Immunol 22: 1819-1825.
72. Boots AMH, Hubers H, Kouwijzer M, Zandbrink LD, Westrek-Esselink BM, et al. (2007) Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263-275) epitope: an MHC anchor variant peptide for immune modulation. Arthritis Res Ther pp. 9.
73. Falcioni F, Ito K, Vidovic D, Belunis C, Campbell R, et al. (1999) Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules. Nat Biotechnol 17: 562-567.
74. Kersh GJ, Miley MJ, Nelson CA, Grakoui A, Horvath S, et al. (2001) Structural and functional consequences of altering a peptide MHC anchor residue. J Immunol 166: 3345-3354.
75. Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, et al. (1998) Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol 161: 3589-3595.
76. Ryan KR, McNeil LK, Dao C, Jensen PE, Evavold BD, (2004) Modification of peptide interaction with MHC creates TCR partial agonists. Cell Immunol 227: 70-78.
77. Margot CD, Ford ML, Evavold BD, (2005) Amelioration of established experimental autoimmune encephalomyelitis by an MHC anchor-substituted variant of proteolipid protein 139-151. J Immunol 174: 3352-3358.
78. Ford ML, Evavold BD, (2003) Regulation of polyclonal T cell responses by an MHC anchor-substituted variant of myelin oligodendrocyte glycoprotein 35-55. J Immunol 171: 1247-1254.
79. Jensen T, Nielsen M, Gad M, Hansen P, Komba S, et al. (2001) Radically Altered T Cell Receptor Signaling in Glycopeptide-Specific T Cell Hybridoma Induced by Antigen with Minimal Differences in the Glycan Group. Eur J Immunol 31: 3197-3206.
80. Gad M, Jensen T, Gagne R, Komba S, Daugaard S, et al. (2003) MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue. Eur J Immunol 33: 1624-1632.
81. Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, et al. (1998) Ligand recognition by αβ T cell receptors. Annu Rev Immunol 16: 523-544.
82. Matsui K, Boniface JJ, Steffner P, Reay PA, Davis MM, (1994) Kinetics of T-Cell Receptor Binding to Peptide/I-Ek Complexes: Correlation of the Dissociation Rate with T-Cell Reponsiveness. Proc Natl Acad Sci USA 91: 12862-12866.
83. Lyons DS, Lieberman SA, Hampl J, Boniface JJ, Chien Y, et al. (1996) A TCR Binds to Antagonist Ligands with Lower Affinities and Faster Dissociation Rates Than to Agonists. Immunity 5: 53-61.
84. Kersh GJ, Kersh EN, Fremont DH, Allen PM, (1998) High- and Low-Potency Ligands with Similar Affinities for the TCR: The Importance of Kinetics in TCR Signaling. Immunity 9: 817-826.
85. Tang B, Zhou J, Park JE, Cullins D, Yi AK, et al. (2009) T cell receptor signaling induced by an analog peptide of type II collagen requires activation of Syk. Clin Immunol 133: 145-153.
86. Myers LK, Sakurai Y, Tang B, He XW, Rosloniec EF, et al. (2002) Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice. Arthritis and Rheum 46: 3369-3377.
87. Sakurai Y, Brand DD, Tang B, Rosloniec EF, Stuart JM, et al. (2006) Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res Ther pp. 8.
88. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC, (1997) X-Ray Crystal Structure of HLA-DR4 (DRA*0101, DRB1*0401) Complexed with a Peptide from Human Collagen II. Immunity 7: 473-481.